Navigation Links
Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
Date:6/11/2009

R 2009 showed that continued treatment with belimumab (BENLYSTA) is associated with sustained improvement or stabilization of SLE disease activity and with decreased frequency of SLE disease flares in serologically active patients through four years of treatment. The overall incidence of adverse events (in general and by system organ class), serious adverse events, infections, malignancies and laboratory abnormalities decreased or stabilized over time from Week 52 to Week 208.

The evidence of sustained clinical effect from Week 52 to Week 208 in serologically active patients who were treated with belimumab from initiation of the Phase 2 study includes:

  • An increase from 46% to 57% in the response rate selected as the primary efficacy endpoint of the Phase 3 trials (defined by an improvement in SELENA SLEDAI score of 4 points or greater, no BILAG worsening, and no worsening in Physician's Global Assessment; post hoc; intention-to-treat analysis).
  • A decrease from 62% to 16% in the overall frequency of SLE disease flares, and from 8% to 1% in the frequency of severe disease flares, as measured by the SELENA SLEDAI Flare Index.
  • A decrease from 23% to 5% in the frequency of patients experiencing one new BILAG A organ domain score (which would indicate a severe flare of lupus disease activity) or more than one new BILAG B organ domain score (which would indicate a moderate flare of disease activity).

The data presented at EULAR 2009 suggest that belimumab was generally well tolerated and may be safely administered long-term in patients with SLE. By Week 208, overall belimumab exposure was 1192 patient years. The incidence rates per 100 patients in all adverse event categories, including serious adverse events, overall adverse events, and serious infections, were similar for belimumab and placebo during the 52-week double-blind period, a
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Printing New Organs: Foundation Funds Medical Technology That Replicates Human Tissue
2. New MIT radio chip mimics human ear
3. deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease
4. Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement
5. Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. STEMCELL Technologies Introduces a New Animal Component-Free, Serum-Free Medium for Culturing Human Mesenchymal Stem Cells
8. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
9. Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2009 Financial Results
10. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
11. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery company, ... Memorandum of Understanding with the Feinstein Institute for ... York to collaborate with the objective ... The collaboration brings together the drug discovery ... expertise of the Feinstein Institute in neurosciences and ...
(Date:4/17/2015)... WI (PRWEB) April 17, 2015 ... sales and marketing support for the powerful Orthogonal ... the Chemical Genomics Center at the Lankenau Institute ... LCGC’s mission is to measurably improve successful drug ... HTS, by offering rare, drug-like libraries available nowhere ...
(Date:4/16/2015)... Mass. (PRWEB) April 16, 2015 ... smart data solutions driven by Semantic Web technology, ... of specialist information and services for the academic ... announced that its joint solution ‘Smart Data Lake ... a finalist for the 2015 Bio-IT ‘Best of ...
(Date:4/16/2015)... 16, 2015 Proove Biosciences , ... of BIO Contest for the 2015 BIO International ... 2015 BIO International Convention will take place June 15-18 ... the Buzz of BIO contest, industry leaders will be ... at the conference. The community voting period began on ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3
... Nov. 14, 2011 Pharmasset, Inc. (Nasdaq: ... discovering, developing, and commercializing novel drugs to treat viral ... the fiscal year ended September 30, 2011. At fiscal ... cash equivalents and used $21.7 million of our cash ...
... inVentiv Health, Inc., offering best-in-class clinical, commercial ... today that it has been selected by the ... operations support, as well as recruiting and sales ... for Type 2 diabetes. inVentiv ...
... Nov. 14, 2011 Nile Therapeutics, Inc. (OTCQB: NLTX), ... failure patients, today announced its third quarter financial results ... of 2011, Nile reported research and development collaboration income ... as compared to none in the third quarter of ...
Cached Biology Technology:Pharmasset Reports Fiscal Year End 2011 Financial Results 2Pharmasset Reports Fiscal Year End 2011 Financial Results 3Pharmasset Reports Fiscal Year End 2011 Financial Results 4Pharmasset Reports Fiscal Year End 2011 Financial Results 5Pharmasset Reports Fiscal Year End 2011 Financial Results 6Pharmasset Reports Fiscal Year End 2011 Financial Results 7Pharmasset Reports Fiscal Year End 2011 Financial Results 8inVentiv Health Selected to Provide Sales Operations Support for Santarus 2inVentiv Health Selected to Provide Sales Operations Support for Santarus 3inVentiv Health Selected to Provide Sales Operations Support for Santarus 4Nile Therapeutics Reports 2011 Third Quarter Financial Results 2Nile Therapeutics Reports 2011 Third Quarter Financial Results 3Nile Therapeutics Reports 2011 Third Quarter Financial Results 4Nile Therapeutics Reports 2011 Third Quarter Financial Results 5
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Iowa A national panel led by Iowa ... research and develop technologies that capture, use and ... development and national security. The 33-member National ... for the first time in Chicago. Participants represented ...
... ferus) has been reduced to only three locations world-wide: two ... Mongolia (Great Gobi A Specially Protected Area). The Great ... unique desert environment that is home to several rare or ... the Gobi bear ( Ursus arctos gobiensis ), the snow ...
... the technology include the ability to label genuine ... difficult to counterfeit. Printers can reduce the use ... can create striking packages that are environmentally friendly. ... which can be made more decorative without compromising ...
Cached Biology News:Iowa State engineers establish national panel to advance a carbon negative economy 2Iowa State engineers establish national panel to advance a carbon negative economy 3Catching camels in the Gobi 2Catching camels in the Gobi 3Ecological light scattering film for brand protection, packages and consumer products 2
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Reacts with methylated DNA from plants and vertebrates...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Biology Products: